Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, November 25, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
  Videos

Return

Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
SELECTBIO

The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
How A Mutant Gene Can Cause Deafness
Scientists at The Scripps Research Institute (TSRI) have discovered how one gene is essential to hearing, uncovering a cause of deafness and suggesting new avenues for therapies.
Precisely Off The Mark
Possible cause discovered for failure of targeted liver cancer therapies.
Schizophrenia May be Triggered by Excess Protein, Rutgers Study Finds
Neuroscientist Bonnie Firestein says too much causes abnormalities in brain development.
Brain-dwelling Worm in UK Man's Head Sequenced
Tapeworm removed from UK resident's brain reveals genetic secrets of an elusive Far East parasite.
Similarities and Striking Differences Found Between Mouse and Human Genome
Comparisons of both genomes’ inner workings may lead to a better use of mouse models.
Novel Cancer Vaccine Approach for Brain Tumors
Researchers unravel the mechanisms behind a novel cancer vaccine for brain tumors, paving the way for further development.
Marching to Our Own Sequences
Study finds DNA replication timing varies among people.
New Test Developed at Dana-Farber/Brigham and Women's Cancer Center
Rapid Heme Panel - A high-tech genetic test that speeds treatment decisions for blood cancer patients.
Researchers Silence Leading Cancer-Causing Gene
A novel siRNA-based molecule successfully targets KRAS, a well-studied but hard to halt protein important for cancer development and metastasis.
Tumor Suppressor Also Inhibits Key Property Of Stem Cells
The retinoblastoma protein inhibits cancer by controlling cell division. Now, researchers have shown that it also binds to and inhibits genes necessary for pluripotency.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv